The trial involved 405 participants, divided into three groups: one following the 5:2 fasting diet with meal replacements (MR) and the other two taking either metformin or empagliflozin (drugs to treat Type 2 diabetes). Those on the 5:2 intermittent fasting diet had two non-consecutive fasting days each week, during which they consumed a low-calorie meal replacement product, limiting intake to 500 calories for women and 600 calories for men. On the other five days, they ate their usual breakfast and lunch but had a different meal replacement product for dinner while monitoring their overall calorie intake.
All participants received comprehensive dietary and exercise guidance, along with general diabetes education from nutritionists and research physicians. Over 16 weeks, participants on the 5:2 intermittent fasting diet experienced a significant drop in hemoglobin A1c (HbA1c) levels—a key measure of blood sugar control. The fasting group had an average reduction of 1.
9 percent, compared to 1.6 percent in the metformin group and 1.5 percent in the empagliflozin group.
The study also reported significant weight loss for those on the fasting diet. Participants in the 5:2 group lost an average of 21 pounds, compared to 12 pounds in the metformin group and 13 pounds in the empagliflozin group. A Manageable Approach Start Gradually: If you’re new to fasting, ease into it by gradually reducing your calorie intake on fasting days.
This can help your body adjust and make the trans.
